secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2025-09-18T23:59:59+00:00
Accession:  0001999371-25-013498
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix completes positive Pre-IND meeting with FDA for TNX-102 SL in MDD; IND filing Q4 2025
--------------------------------------------------------------------------------

- FDA found proposed long-term safety data collection plan generally reasonable, potentially streamlining development.
- Company plans to pursue sNDA to expand TNX-102 SL indication to include MDD.
- IND filing for TNX-102 SL in MDD planned for Q4 2025; Phase 2 trial expected shortly after.
- TNX-102 SL (sublingual cyclobenzaprine HCl) is already FDA-approved for fibromyalgia as Tonmya.
- Decision based on exploratory findings that improving sleep quality may positively impact depressive symptoms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125013498/0001999371-25-013498-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125013498/tnxp_8k-091825.htm
  HTML page:      https://secwatch.observer/filing/0001999371-25-013498

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer